BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 11368001)

  • 1. [Acute coronary syndrome. Early lipid reduction decreases risk of recurrence].
    MMW Fortschr Med; 2001 Apr; 143(16):60. PubMed ID: 11368001
    [No Abstract]   [Full Text] [Related]  

  • 2. Improved outcome after acute coronary syndromes with an intensive versus standard lipid-lowering regimen: results from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) trial.
    Rouleau J
    Am J Med; 2005 Dec; 118 Suppl 12A():28-35. PubMed ID: 16356805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Short- and long-term effects of intensified versus conventional antilipidemic therapy in patients with coronary heart disease. Results from the Lipid-Coronary Artery Disease (L-CAD) Study].
    Arntz HR; Wunderlich W; Schnitzer L; Stern R; Fischer F; Agrawal R; Linderer T; Schultheiss HP
    Z Kardiol; 1999 Aug; 88(8):582-90. PubMed ID: 10506395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials).
    Murphy SA; Cannon CP; Wiviott SD; de Lemos JA; Blazing MA; McCabe CH; Califf RM; Braunwald E
    Am J Cardiol; 2007 Oct; 100(7):1047-51. PubMed ID: 17884359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is there a 'treatment gap' in acute coronary syndromes?
    Krause BR; Newton RS
    Curr Opin Investig Drugs; 2003 Sep; 4(9):1046-7. PubMed ID: 14582446
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of pravastatin compared with placebo initiated within 24 hours of onset of acute myocardial infarction or unstable angina: the Pravastatin in Acute Coronary Treatment (PACT) trial.
    Thompson PL; Meredith I; Amerena J; Campbell TJ; Sloman JG; Harris PJ;
    Am Heart J; 2004 Jul; 148(1):e2. PubMed ID: 15215811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Lowering cholesterol in the elderly--yes, no, or maybe?].
    Gogol M
    MMW Fortschr Med; 2006 Mar; 148(12):40-3. PubMed ID: 16626005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relation between soluble intercellular adhesion molecule-1, statin therapy, and long-term risk of clinical cardiovascular events in patients with previous acute coronary syndrome (from PROVE IT-TIMI 22).
    Ray KK; Morrow DA; Shui A; Rifai N; Cannon CP
    Am J Cardiol; 2006 Oct; 98(7):861-5. PubMed ID: 16996863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [New studies of high dosage statins and fibrates. How is lipid lowering therapy changing? (interview by Dr. med. Dirk Einecke)].
    Klose G
    MMW Fortschr Med; 2005 Dec; 147(49-50):20. PubMed ID: 16401005
    [No Abstract]   [Full Text] [Related]  

  • 10. High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial.
    Olsson AG; Schwartz GG; Szarek M; Sasiela WJ; Ezekowitz MD; Ganz P; Oliver MF; Waters D; Zeiher A
    Eur Heart J; 2005 May; 26(9):890-6. PubMed ID: 15764620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Differentiated treatment of diabetics with an acute coronary syndrome].
    Hamm CW; Hamann A
    Dtsch Med Wochenschr; 2006 Nov; 131(47 Suppl 7):S208-10. PubMed ID: 17109250
    [No Abstract]   [Full Text] [Related]  

  • 12. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study.
    Kinlay S; Schwartz GG; Olsson AG; Rifai N; Leslie SJ; Sasiela WJ; Szarek M; Libby P; Ganz P;
    Circulation; 2003 Sep; 108(13):1560-6. PubMed ID: 12975259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Lower, lower, lower. The LDL goal value of 200 mg/dl is still much too high].
    Einecke D
    MMW Fortschr Med; 2004 Mar; 146(13):4-5. PubMed ID: 15219114
    [No Abstract]   [Full Text] [Related]  

  • 14. [Type 2 diabetic: risk same as after infarct. With LDL not only the quantity counts].
    MMW Fortschr Med; 2004 Jun; 146(24):4. PubMed ID: 15366509
    [No Abstract]   [Full Text] [Related]  

  • 15. Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trial.
    Sabatine MS; Morrow DA; Giugliano RP; Murphy SA; Demopoulos LA; DiBattiste PM; Weintraub WS; McCabe CH; Antman EM; Cannon CP; Braunwald E
    Circulation; 2004 Feb; 109(7):874-80. PubMed ID: 14757697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
    Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
    Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [CSE inhibitors after coronary event. How soon administered?].
    MMW Fortschr Med; 2001 May; 143(22):52. PubMed ID: 11460407
    [No Abstract]   [Full Text] [Related]  

  • 18. The role of inflammation in acute coronary syndromes: review of the literature.
    Elhajj II; Haydar AA; Hujairi NM; Goldsmith DJ
    J Med Liban; 2004; 52(2):96-102. PubMed ID: 15884689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pravastatin in acute ischaemic syndromes: results of a randomised placebo-controlled trial.
    Den Hartog FR; Van Kalmthout PM; Van Loenhout TT; Schaafsma HJ; Rila H; Verheugt FW
    Int J Clin Pract; 2001 Jun; 55(5):300-4. PubMed ID: 11452676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are Canadian guidelines for cholesterol lowering in high-risk patients optimal?
    Fitchett DH; Leiter LA; Tardif JC; Goodman S; Langer A
    Can J Cardiol; 2005 Jan; 21(1):85-90. PubMed ID: 15685308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.